NEWS
MiNK’s iNKT Cell Therapy Shows Potential for Optimal Multi-Combination for Resistant Solid Cancers at SITC 2024
MiNK Therapeutics presented new data at SITC 2024 showcasing their iNKT cell therapy programs. Their lead therapy agenT-797, alone or combined with anti-PD-1, demonstrated durable disease control in heavily pretreated patients. When combined with bispecific engagers targeting MUC16, HER2, Claudin 18.2, and DLL3, it showed enhanced T-cell activation and tumor cell killing.
The company also presented data on their PRAME-TCR iNKT therapy, designed to treat PRAME-positive solid tumors without requiring lymphodepletion or HLA-matching. A Phase 2 trial of agenT-797 is currently enrolling patients with advanced gastroesophageal cancer, with results expected in 2025.
The company also presented data on their PRAME-TCR iNKT therapy, designed to treat PRAME-positive solid tumors without requiring lymphodepletion or HLA-matching. A Phase 2 trial of agenT-797 is currently enrolling patients with advanced gastroesophageal cancer, with results expected in 2025.
免責事項：このコミュニティは、Moomoo Technologies Inc.が教育目的でのみ提供するものです。
さらに詳しい情報
コメント
サインインコメントをする
Spread kindness and love. Life is short. Don’t let greed eat you.
2877フォロワー
108フォロー中
30K訪問者
フォロー